Sanz-Moreno et al. found that anti-HER2 treatment and acquired resistance to anti-HER2 treatment elevated RANK (Receptor activator of nuclear factor kappa) expression levels in HER2-positive cell lines and patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.